Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B

Ronald B Goldberg, D. Rabin, A. N. Alexander, G. C. Doelle, G. S. Getz

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Men have lower high density lipoprotein (HDL) and higher low density lipoprotein (LDL) levels than women. To dynamically evaluate the role of endogenous testosterone on the lipoprotein profile, eight normal men received a long-acting gonadotropin releasing hormone analog (LHRH(A)) for 10 weeks by SC injection. Plasma testosterone levels were acutely lowered below 1 ng/ml after 4 weeks of LHRH(A) treatment and remained depressed at this level for the duration of administration of the analog. There were prompt increases in total cholesterol [baseline vs. peak (milligrams per dl) mean ± SEM, 177 ± 18 vs. 208 ± 22; P<0.005], apoprotein B (apo B; 69 ± 12 vs. 97 ± 13; P<0.05), HDL-cholesterol (23 ± 2 vs. 33 ± 2; P<0.005), and apo A-I (80 ± 7 vs. 112 ± 5; P<0.005), but not in apo A-II (40 ± 3 vs. 40 ± 4; P=NS) levels. The peaks occurred after 10 weeks of treatment and were followed by a fall in these values after discontinuing LHRH(A). These changes were largely prevented in a second study (six men) in which LHRH(A) was administered together with im testosterone enanthate, which was given every 2 weeks. These results show that suppression of endogenous testosterone leads to increases in HDL and LDL, demonstrating that testosterone has an important effect on lipoprotein metabolism and plays a key role in defining the lipoprotein profile in men.

Original languageEnglish
Pages (from-to)203-207
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume60
Issue number1
StatePublished - Mar 13 1985

Fingerprint

Apoproteins
Gonadotropin-Releasing Hormone
HDL Cholesterol
Testosterone
Plasmas
HDL Lipoproteins
Lipoproteins
Serum
Apolipoproteins B
LDL Lipoproteins
Apolipoprotein A-II
Apolipoprotein A-I
Metabolism
Cholesterol
Scanning electron microscopy
Injections
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B. / Goldberg, Ronald B; Rabin, D.; Alexander, A. N.; Doelle, G. C.; Getz, G. S.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 60, No. 1, 13.03.1985, p. 203-207.

Research output: Contribution to journalArticle

@article{91c5acec9810476f964063f98df823f7,
title = "Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B",
abstract = "Men have lower high density lipoprotein (HDL) and higher low density lipoprotein (LDL) levels than women. To dynamically evaluate the role of endogenous testosterone on the lipoprotein profile, eight normal men received a long-acting gonadotropin releasing hormone analog (LHRH(A)) for 10 weeks by SC injection. Plasma testosterone levels were acutely lowered below 1 ng/ml after 4 weeks of LHRH(A) treatment and remained depressed at this level for the duration of administration of the analog. There were prompt increases in total cholesterol [baseline vs. peak (milligrams per dl) mean ± SEM, 177 ± 18 vs. 208 ± 22; P<0.005], apoprotein B (apo B; 69 ± 12 vs. 97 ± 13; P<0.05), HDL-cholesterol (23 ± 2 vs. 33 ± 2; P<0.005), and apo A-I (80 ± 7 vs. 112 ± 5; P<0.005), but not in apo A-II (40 ± 3 vs. 40 ± 4; P=NS) levels. The peaks occurred after 10 weeks of treatment and were followed by a fall in these values after discontinuing LHRH(A). These changes were largely prevented in a second study (six men) in which LHRH(A) was administered together with im testosterone enanthate, which was given every 2 weeks. These results show that suppression of endogenous testosterone leads to increases in HDL and LDL, demonstrating that testosterone has an important effect on lipoprotein metabolism and plays a key role in defining the lipoprotein profile in men.",
author = "Goldberg, {Ronald B} and D. Rabin and Alexander, {A. N.} and Doelle, {G. C.} and Getz, {G. S.}",
year = "1985",
month = "3",
day = "13",
language = "English",
volume = "60",
pages = "203--207",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B

AU - Goldberg, Ronald B

AU - Rabin, D.

AU - Alexander, A. N.

AU - Doelle, G. C.

AU - Getz, G. S.

PY - 1985/3/13

Y1 - 1985/3/13

N2 - Men have lower high density lipoprotein (HDL) and higher low density lipoprotein (LDL) levels than women. To dynamically evaluate the role of endogenous testosterone on the lipoprotein profile, eight normal men received a long-acting gonadotropin releasing hormone analog (LHRH(A)) for 10 weeks by SC injection. Plasma testosterone levels were acutely lowered below 1 ng/ml after 4 weeks of LHRH(A) treatment and remained depressed at this level for the duration of administration of the analog. There were prompt increases in total cholesterol [baseline vs. peak (milligrams per dl) mean ± SEM, 177 ± 18 vs. 208 ± 22; P<0.005], apoprotein B (apo B; 69 ± 12 vs. 97 ± 13; P<0.05), HDL-cholesterol (23 ± 2 vs. 33 ± 2; P<0.005), and apo A-I (80 ± 7 vs. 112 ± 5; P<0.005), but not in apo A-II (40 ± 3 vs. 40 ± 4; P=NS) levels. The peaks occurred after 10 weeks of treatment and were followed by a fall in these values after discontinuing LHRH(A). These changes were largely prevented in a second study (six men) in which LHRH(A) was administered together with im testosterone enanthate, which was given every 2 weeks. These results show that suppression of endogenous testosterone leads to increases in HDL and LDL, demonstrating that testosterone has an important effect on lipoprotein metabolism and plays a key role in defining the lipoprotein profile in men.

AB - Men have lower high density lipoprotein (HDL) and higher low density lipoprotein (LDL) levels than women. To dynamically evaluate the role of endogenous testosterone on the lipoprotein profile, eight normal men received a long-acting gonadotropin releasing hormone analog (LHRH(A)) for 10 weeks by SC injection. Plasma testosterone levels were acutely lowered below 1 ng/ml after 4 weeks of LHRH(A) treatment and remained depressed at this level for the duration of administration of the analog. There were prompt increases in total cholesterol [baseline vs. peak (milligrams per dl) mean ± SEM, 177 ± 18 vs. 208 ± 22; P<0.005], apoprotein B (apo B; 69 ± 12 vs. 97 ± 13; P<0.05), HDL-cholesterol (23 ± 2 vs. 33 ± 2; P<0.005), and apo A-I (80 ± 7 vs. 112 ± 5; P<0.005), but not in apo A-II (40 ± 3 vs. 40 ± 4; P=NS) levels. The peaks occurred after 10 weeks of treatment and were followed by a fall in these values after discontinuing LHRH(A). These changes were largely prevented in a second study (six men) in which LHRH(A) was administered together with im testosterone enanthate, which was given every 2 weeks. These results show that suppression of endogenous testosterone leads to increases in HDL and LDL, demonstrating that testosterone has an important effect on lipoprotein metabolism and plays a key role in defining the lipoprotein profile in men.

UR - http://www.scopus.com/inward/record.url?scp=0021927023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021927023&partnerID=8YFLogxK

M3 - Article

C2 - 3917267

AN - SCOPUS:0021927023

VL - 60

SP - 203

EP - 207

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -